A Feasibility Trial of Virtual Reality Neurofeedback for Adolescents With Migraine
Part of paid clinical trials in Kansas City, Missouri.
- Sponsor
- Children's Mercy Hospital Kansas City
- Study ID
- NCT07454798
- Status
- Recruiting
Conditions
- Headache Disorders, Primary
- Migraine
Eligibility Criteria
- Sex
- ALL
- Age
- 10 Years - 16 Years
- Healthy Volunteers
- Not accepted
Interventions
- Immersive Neurofeedback Self-Regulation Training (INSeRT) — BEHAVIORALA home-based behavioral intervention that integrates real-time EEG signals from a wearable headband into a virtual reality environment to provide neurofeedback during brief self-regulation training sessions. Participants complete sessions three times per week for approximately 8 minutes per session over 4 weeks.
- Virtual Reality Imagery (No Neurofeedback) — BEHAVIORALA home-based virtual reality imagery experience delivered without neurofeedback or guided relaxation training. Participants complete sessions three times per week for approximately 8 minutes per session over 4 weeks.
Study Details
The goal of this clinical trial is to learn whether a home-based virtual reality (VR) neurofeedback program is feasible and acceptable for adolescents with migraine. The study will also explore whether the program may improve headache-related outcomes. The main questions it aims to answer are: Is it feasible to enroll, randomize, and retain adolescents with migraine in this study? Do participants complete the VR sessions and study procedures as intended? Are there preliminary signals that the VR neurofeedback program may improve headache-related disability and symptoms? Researchers will compare Immersive Neurofeedback Self-Regulation Training (INSeRT), which uses brain activity recorded from a wearable electroencephalogram (EEG) headband to guide the VR experience, to a comparison VR program that presents immersive imagery without neurofeedback or guided relaxation training. Participants will: Complete a 4-week baseline period that includes headache logs, questionnaires, and a laboratory EEG assessment Be randomly assigned to one of two VR programs Complete VR sessions at home three times per week for 4 weeks Complete questionnaires at the end of treatment and again approximately 3 months later Repeat the laboratory EEG assessment at the end of treatment
Key Dates
- Start date
- May 13, 2026
- Status verified
- Jun 2026
- Primary completion
- May 31, 2028
- Completion
- May 31, 2028
Study Design
- Enrollment
- 38 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Immersive Neurofeedback Self-Regulation Training (INSeRT)Participants receive a home-based immersive virtual reality intervention that integrates real-time EEG signals from a wearable headband to provide neurofeedback during virtual reality sessions. Sessions are completed three times per week for approximately 8 minutes per session over 4 weeks.
- Active Comparator: Virtual Reality Imagery (No Neurofeedback)Participants receive a home-based immersive virtual reality imagery experience without neurofeedback and without guided relaxation training. Sessions are completed three times per week for approximately 8 minutes per session over 4 weeks.
Primary Outcome Measure
Feasibility of Recruitment and Enrollment [ Time Frame: From study initiation through completion of enrollment (approximately 24 months) ]
Central Contacts
- Mark A Connelly, PhD816-234-3193
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Children's Mercy | Kansas City | Missouri | 64108 |
Find similar trials in Kansas City, MO
Related Studies
- Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)PHASE3 · Recruiting · AbbVie · Huntsville, Alabama
- Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Pediatric Participants (Ages 6-17)PHASE3 · Enrolling By Invitation · AbbVie · Huntsville, Alabama
- Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric SubjectsPHASE3 · Recruiting · Pfizer · Fort Smith, Arkansas
- Migraine in AdolescentsRecruiting · Washington University School of Medicine · St Louis, Missouri